Jackson, MS - New research suggests that mycophenolate mofetil (MMF) can be used in the management of autoimmune inflammatory myopathy. The finding, published in the March 2005 issue of Rheumatology, ...
MIAMI, Feb. 03, 2026 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed to modulate the immune system, today ...
Idiopathic inflammatory myopathies (IIM) represent a heterogeneous group of autoimmune disorders primarily characterised by progressive muscle weakness and inflammation, but with potential involvement ...
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Clinical trials exploring intravenous immunoglobulin and Janus kinase inhibition headline a robust ...
Despite modern medical therapies, multiorgan idiopathic inflammatory myopathies (IIM) are associated with reduced quality of life and life expectancy. A systematic review of all published ...
Early-onset IBM challenges age-centric diagnostic criteria, with symptoms appearing in patients younger than 46. Younger IBM patients show a higher rate of mitochondrial DNA mutations, indicating ...
Idiopathic inflammatory myopathies (IIMs) comprise a group of inflammatory disorders in which there is chronic inflammation of skeletal muscle. This is then followed by muscle weakness. One type of ...
Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase ...
History gathering should solicit the patient’s abilities or limitations with these activities of daily living (ADLs). The patient may have mild arthralgias. Lungs are the most common extra muscular ...
Dermatomyositis is a rare autoimmune disease that typically affects the skin, muscle and respiratory system. Patients with dermatomyositis usually require prompt treatment with intense ...
Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy and a significant reduction in steroid use within 6 months in Idiopathic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results